Get the Stockscreener App
1.15
10.16%
-0.13
After Hours:
1.16
0.01
+0.87%
Xilio Therapeutics Inc stock is currently priced at $1.15, with a 24-hour trading volume of 338.67K.
It has seen a -10.16% decreased in the last 24 hours and a +67.88% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.25 pivot point. If it approaches the $1.15 support level, significant changes may occur.
Xilio Therapeutics Inc Stock (XLO) Financials Data
Xilio Therapeutics Inc (XLO) Net Income 2024
XLO net income (TTM) was -$81.22 million for the quarter ending September 30, 2023, a +4.96% increase year-over-year.
Xilio Therapeutics Inc (XLO) Cash Flow 2024
XLO recorded a free cash flow (TTM) of -$74.41 million for the quarter ending September 30, 2023, a +2.60% increase year-over-year.
Xilio Therapeutics Inc (XLO) Earnings per Share 2024
XLO earnings per share (TTM) was -$2.96 for the quarter ending September 30, 2023, a +12.43% growth year-over-year.
Xilio Therapeutics Inc Stock (XLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 08 '24 |
Sale |
0.64 |
733 |
469 |
2,019,563 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 08 '24 |
Sale |
0.64 |
267 |
171 |
734,546 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 12 '24 |
Sale |
0.83 |
1,540 |
1,278 |
2,020,296 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 12 '24 |
Sale |
0.83 |
560 |
465 |
734,813 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 11 '24 |
Sale |
0.87 |
1,566 |
1,362 |
2,021,836 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 11 '24 |
Sale |
0.87 |
569 |
495 |
735,373 |
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Zacks Investment Research
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Sizing Your Penny Stocks Position, 3 Tips
PennyStocks
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Gold Gains 1%; Walgreens Narrows Earnings Forecast
Benzinga
About Xilio Therapeutics Inc
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
COMPANY PROFILE
NameXilio Therapeutics Inc
SectorHealthcare (1203)
IndustryBiotechnology (691)
Web
Phone617-430-4680
Employee66
Address828 Winter Street, Waltham, United States (02451)
1.85%
1.31%
Cap:
|
Volume (24h):